StockVS

NYSE American · Medical Instruments & Supplies · USD

Regentis Biomaterials Ltd. (RGNT) Stock Analysis

Regentis Biomaterials Ltd. (RGNT) is a Medical Instruments & Supplies stock listed on NYSE American and quoted in US Dollar.

RGNT

$1.97

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RGNT with… →

RGNT Key Statistics

As of Sep 4, 2026
Trading
Open
$1.94
Previous Close
$1.97
Day's Range
1.94–2.00
52-Week Range
1.23–15.50
Volume
15.90K
Valuation
Market Cap
$13.84M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−24.16
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$13.65M−384.27%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
7.02M
Dividend and dates
Avg Volume
5.40M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RGNT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−70.77%
2025 (partial year)−10.13%

As of September 4, 2026.

RGNT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$13.65M
2024$0.00$4.80M
2023$0.00−$4.13M
2022$0.00−$1.45M
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00−$8.62M−$13.65M
2024$0.00$932.00K$4.80M
2023$0.00−$1.93M−$4.13M
2022$0.00−$1.41M−$1.45M

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RGNT Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricRGNTMedical Instruments & Supplies medianvs median
Profit margin0.00%0.85%0.8 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Regentis Biomaterials Ltd. (RGNT) at $13.84M. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector.

RGNT last closed at $1.97 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $1.23 to $15.50. The latest close sits 59.9% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $13.65M. The reported profit margin is 0%. That is 0.8 percentage points below the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to −24.16.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on December 4, 2025, and the total return since then is −73.73%.

Growth & Income

The record shows no dividend for RGNT.

2026 is still running; the price is −70.77% year to date.

Peer Comparison

Regentis Biomaterials Ltd. (RGNT) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Regentis Biomaterials Ltd. RGNT $13.84M
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Regentis Biomaterials Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Visit website →